[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 463, "maxAge": 86400, "priceHint": 4, "previousClose": 3.86, "open": 3.94, "dayLow": 3.82, "dayHigh": 4.025, "regularMarketPreviousClose": 3.86, "regularMarketOpen": 3.94, "regularMarketDayLow": 3.82, "regularMarketDayHigh": 4.025, "beta": 2.018, "forwardPE": -5.8923078, "volume": 2775049, "regularMarketVolume": 2775049, "averageVolume": 1566319, "averageVolume10days": 1645870, "averageDailyVolume10Day": 1645870, "bid": 3.81, "ask": 3.86, "bidSize": 200, "askSize": 200, "marketCap": 1018917888, "fiftyTwoWeekLow": 2.01, "fiftyTwoWeekHigh": 7.45, "priceToSalesTrailing12Months": 97.067535, "fiftyDayAverage": 4.214, "twoHundredDayAverage": 4.621475, "currency": "USD", "enterpriseValue": 540219392, "floatShares": 131690544, "sharesOutstanding": 266036000, "sharesShort": 3252017, "sharesShortPriorMonth": 4069436, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.012200001, "heldPercentInsiders": 0.18030001, "heldPercentInstitutions": 0.75052, "shortRatio": 1.56, "shortPercentOfFloat": 0.0165, "impliedSharesOutstanding": 266036000, "bookValue": 2.189, "priceToBook": 1.7496574, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -221262000, "trailingEps": -1.21, "forwardEps": -0.65, "enterpriseToRevenue": 51.464, "enterpriseToEbitda": -3.133, "52WeekChange": 0.48449612, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.83, "targetHighPrice": 16.0, "targetLowPrice": 6.9, "targetMeanPrice": 10.69, "targetMedianPrice": 11.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 758529024, "totalCashPerShare": 2.851, "ebitda": -172432992, "totalDebt": 279830016, "quickRatio": 17.972, "currentRatio": 18.286, "totalRevenue": 10497000, "debtToEquity": 48.078, "revenuePerShare": 0.056, "returnOnAssets": -0.16426, "returnOnEquity": -0.52126, "freeCashflow": -129865000, "operatingCashflow": -143682000, "revenueGrowth": 6.81, "operatingMargins": -3.8407502, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]